
Opinion|Videos|August 20, 2024
Key Takeaways for Biosimilar Utilization
The panelists provide their closing thoughts, highlighting key considerations around biosimilar.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Thanks to all of you for this rich and informative discussion. Before we conclude I’d like to get final thoughts from each of you…
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
4
Value-Based Care Interventions and Management of CKD Progression
5